Autoimmune hemolytic anemia (AIHA) is a rare, but clinically significant complication following hematopoietic stem cell transplantation (HSCT). It is characterized by hemolysis due to antibodies produced by the donor's immune system against donor red cell antigens. The 3-year cumulative incidence of AIHA is 4.44% in adults; however, 75% of patients develop AIHA during the first post-HSCT year [1] . AIHA after allogeneic HSCT has been associated with a variety of conditions, including chronic graft-versus-host disease (GVHD) [2] , T-cell depletion [3] , and unrelated donor transplants [4] . HSCT from unrelated donors and the development of chronic extensive GVHD were the only independent factors associated with AIHA [1]; however, the incidence of and risk factors for AIHA, as well as its prognosis and response to treatment remain unclear.
To the Editor, Autoimmune hemolytic anemia (AIHA) is a rare, but clinically significant complication following hematopoietic stem cell transplantation (HSCT). It is characterized by hemolysis due to antibodies produced by the donor's immune system against donor red cell antigens. The 3-year cumulative incidence of AIHA is 4.44% in adults; however, 75% of patients develop AIHA during the first post-HSCT year [1] . AIHA after allogeneic HSCT has been associated with a variety of conditions, including chronic graft-versus-host disease (GVHD) [2] , T-cell depletion [3] , and unrelated donor transplants [4] . HSCT from unrelated donors and the development of chronic extensive GVHD were the only independent factors associated with AIHA [1] ; however, the incidence of and risk factors for AIHA, as well as its prognosis and response to treatment remain unclear.
A 56-year-old male was diagnosed with high-risk acute myelogenous leukemia in April 2008. He was administered 8 cycles of chemotherapy, including idarubicin, cytosine arabinoside (ara-C), and sorafenib, and achieved complete remission. He remained in remission for 17 months, and then relapsed. He was treated with ara-C, and clofarabine, and achieved complete remission for the second time.
He received a haploidentical (70% matched) bone marrow transplant (BMT) from his son on 03 March 2010, following conditioning with fludarabine, melphalan, and thiotepa, at the MD Anderson Cancer Center. GVHD prophylaxis was tacrolimus 1 mg p.o. twice daily and mycophenolate mofetil 1000 mg p.o. daily.
Stem cell infusion was uneventful, except for mild hypotension. The patient had mild veno-occlusive disease of the liver that eventually resolved, and several (4-5) episodes of CMV viremia, but no evident GVHD throughout his course. His blood type was A-, but the donor (son) was A+. The patient underwent bone marrow biopsy 3 months after transplantation, which showed 1% blasts and no flow cytometric evidence of relapse. Post-transplant microsatellite polymorphism was compatible with successful engraftment. No chimerism was observed. On post-transplant day 208 he presented with septic/hypotensive shock, and was supported with broad-spectrum antibiotics and intravenous fluids. He did not require mechanical ventilation or vasopressor therapy; however, deep anemia was noted (Hb: 3.8 g dL -1 ) and most of the RBC units cross-matched for transfusion appeared to be incompatible. It was noted that the patient's blood group had converted to A+, suggesting full erythroid donor chimerism. AIHA was diag-nosed, based on fulfillment of all of the following criteria: positive direct antiglobulin test (DAT), negative indirect antiglobulin test (IAT), clinical and laboratory evidence of hemolysis (Table 1) , and exclusion of other causes of immune hemolytic anemia. ) IV was initiated. Plasmapheresis with fresh frozen plasma (FFP) was performed (median exchange volume: 3014 mL) for 4 days. After the 1st, 2nd, and 3rd plasmapheresis, DAT was positive and IAT was negative ( Table 1 ). The reactives for the DAT test were polyspesific for IgG and C3d. Unfortunately, the patient's Hb value fell to 3.2 g dL -1 at that time (Table 1) . IV immunoglobulin (IVIg) 25 g d -1 was administered the same day as the 2 nd and 3rd plasmapheresis (after apheresis). Methylprednisolone was tapered to 40 mg d -1 on the fifth treatment day. As a result, the patient received 17 units of RBC, plasmapheresis 4 times, and IVIg twice during the course of treatment. Two weeks later AIHA was in control without RBC transfusion and the patient was discharged with an Hb value of 8.5 g dL -1 (Table 1) . Methylprednisolone was tapered off within a month. Written informed consent was obtained from the patient.
Sanz et al. reported that most patients receive steroids as a primary treatment for AIHA and that the majority of cases do not respond [1] . Based on the response in the presented patient, plasmapheresis in addition to IVIg and corticosteroid should be considered a viable alternative treatment option in patients with AIHA that develops during the post-transplant period. 
